ALBO - アルビレオ・ファ―マ （Albireo Pharma Inc.） アルビレオ・ファ―マALBOのチャート
ALBOの企業情報
| symbol | ALBO |
|---|---|
| 会社名 | Albireo Pharma Inc （アルビレオ・ファ―マ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 アルビレオ・ファーマ(Albireo Pharma Inc.)（旧名:Biodel Inc.）は臨床段階の生物製薬会社である。同社は孤児小児肝疾患及び他の肝臓・胃腸の疾患と障害を治療するための胆汁酸モジュレーターの開発・商業化に従事する。臨床パイプラインは2つ以上の第II相製品候補と1つの第III相製品候補を含む。同社のパイプラインはA4250、A3384及びElobixibatを含む。A4250は進行性家族肝内胆汁うっ滞（PFIC）等の小児孤児胆汁うっ滞性肝疾患の治療方法として開発される。A3384は胆汁酸吸収不良（BAM）疾患を治療するために開発される。また、Elobixibatは慢性特発性便秘（CIC）を治療するために開発される。A4250とElobixibatは回腸胆汁酸トランスポーター（IBAT）の選択的阻害剤である。同社は19以上のBAM被験者を対象として、A3384のプロトタイプの第II相臨床試験を完了した。 アルビレオ・ファ―マは米国のバイオ医薬品メ―カ―。主に、糖尿病や骨粗しょう症などの内分泌障害 治療薬の開発と商品化に注力する。高分子量のインスリン吸収時間を速くする研究を行っており、超速効型インスリン｢BIOD-123｣や｢BIOD531｣を開発中。本社所在地はコネチカット州ダンバリ―。 Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year. |
| 本社所在地 | 10 Post Office Square Suite 502 South Boston MA 02109 USA |
| 代表者氏名 | David Chiswell デビッドチスウェル |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 857-415-4774 |
| 設立年月日 | 37956 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 22人 |
| url | www.albireopharma.com |
| nasdaq_url | https://www.nasdaq.com/symbol/albo |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -22.81400 |
| 終値（lastsale） | 30.01 |
| 時価総額（marketcap） | 359217539.28 |
| 時価総額 | 時価総額（百万ドル） 367.47680 |
| 売上高 | 売上高（百万ドル） 11.93100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 184.24880 |
| 当期純利益 | 当期純利益（百万ドル） -27.78900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Albireo Pharma Inc revenues increased from $2K to $11.9M. Net loss increased 26% to $16.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $5.8M to $12.6M (expense) General and administrative increase from $3.7M to $8.4M (expense) Non-operating income (expense). |
ALBOのテクニカル分析
ALBOのニュース
Ipsen Pharma: Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 2023/02/22 06:10:00 Finanz Nachrichten
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 Extension allows for the satisfaction of the HSR Act related condition as outlined in the Merger AgreementAlbi…
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome 2023/02/14 13:30:00 GlobeNewswire
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s supplemental New Drug Application (sNDA) and issued a Prescription Drug User Fee Act (PDUFA) action date of June 15, 2023 for a second Bylvay (odevixibat) indication for patients with Alagille syndrome (ALGS). As defined by the FDA, the Priority Review timeline is 6 months and the agency will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. With completed submissions for Bylvay in the U.S. and EU for use in patients with ALGS, the Company anticipates approvals in mid-2023.
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations 2023/02/06 21:53:00 Kwhen Finance
Mirum Pharmaceuticals: In The Spotlight Following Buyout Of Albireo Pharma 2023/02/01 12:00:00 Seeking Alpha
Albireo, Mirum''s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. Find out why I''m bullish on MIRM stock.
Is Albireo Pharma Inc. (NASDAQ: ALBO) A Top Momentum Pick? 2023/01/14 15:30:00 Stocks Register
Albireo Pharma Inc. (NASDAQ:ALBO) price on Friday, January 13, fall -0.09% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $43.90. A look at the stock’s price movement, the close in the last trading session was $43.94, moving within a range at $43.85 and $44.3998. The beta value … Is Albireo Pharma Inc. (NASDAQ: ALBO) A Top Momentum Pick? Read More »
Ipsen Pharma: Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 2023/02/22 06:10:00 Finanz Nachrichten
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 Extension allows for the satisfaction of the HSR Act related condition as outlined in the Merger AgreementAlbi…
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome 2023/02/14 13:30:00 GlobeNewswire
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s supplemental New Drug Application (sNDA) and issued a Prescription Drug User Fee Act (PDUFA) action date of June 15, 2023 for a second Bylvay (odevixibat) indication for patients with Alagille syndrome (ALGS). As defined by the FDA, the Priority Review timeline is 6 months and the agency will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. With completed submissions for Bylvay in the U.S. and EU for use in patients with ALGS, the Company anticipates approvals in mid-2023.
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations 2023/02/06 21:53:00 Kwhen Finance
Mirum Pharmaceuticals: In The Spotlight Following Buyout Of Albireo Pharma 2023/02/01 12:00:00 Seeking Alpha
Albireo, Mirum''s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. Find out why I''m bullish on MIRM stock.
Is Albireo Pharma Inc. (NASDAQ: ALBO) A Top Momentum Pick? 2023/01/14 15:30:00 Stocks Register
Albireo Pharma Inc. (NASDAQ:ALBO) price on Friday, January 13, fall -0.09% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $43.90. A look at the stock’s price movement, the close in the last trading session was $43.94, moving within a range at $43.85 and $44.3998. The beta value … Is Albireo Pharma Inc. (NASDAQ: ALBO) A Top Momentum Pick? Read More »
Ipsen Pharma: Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 2023/02/22 06:10:00 Finanz Nachrichten
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 Extension allows for the satisfaction of the HSR Act related condition as outlined in the Merger AgreementAlbi…
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay® in Alagille Syndrome 2023/02/14 13:30:00 GlobeNewswire
BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s supplemental New Drug Application (sNDA) and issued a Prescription Drug User Fee Act (PDUFA) action date of June 15, 2023 for a second Bylvay (odevixibat) indication for patients with Alagille syndrome (ALGS). As defined by the FDA, the Priority Review timeline is 6 months and the agency will direct overall attention and resources to the evaluation of applications for drugs that, if approved, would be significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. With completed submissions for Bylvay in the U.S. and EU for use in patients with ALGS, the Company anticipates approvals in mid-2023.
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations 2023/02/06 21:53:00 Kwhen Finance
Mirum Pharmaceuticals: In The Spotlight Following Buyout Of Albireo Pharma 2023/02/01 12:00:00 Seeking Alpha
Albireo, Mirum''s only competitor in a billion-dollar market, is being acquired by Ipsen for up to $1.2 billion. Find out why I''m bullish on MIRM stock.
Is Albireo Pharma Inc. (NASDAQ: ALBO) A Top Momentum Pick? 2023/01/14 15:30:00 Stocks Register
Albireo Pharma Inc. (NASDAQ:ALBO) price on Friday, January 13, fall -0.09% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $43.90. A look at the stock’s price movement, the close in the last trading session was $43.94, moving within a range at $43.85 and $44.3998. The beta value … Is Albireo Pharma Inc. (NASDAQ: ALBO) A Top Momentum Pick? Read More »